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Determination of HER2 ampliﬁcation in primary breast cancer using dual-colour chromogenic
in situ hybridization is comparable to ﬂuorescence in situ hybridization: a European
multicentre study involving 168 specimens
Aims: Fluorescence in situ hybridization (FISH) can be
used to reveal several genomic imbalances relevant to
proper cancer diagnosis and to the correct treatment
regime. However, FISH requires expensive and ad-
vanced ﬂuorescence microscopes in addition to exper-
tise in ﬂuorescence microscopy. To determine whether
a newly developed dual-colour chromogenic in situ
hybridization (CISH) method is a suitable alternative to
FISH, we analysed the human epidermal growth factor
receptor 2 gene (HER2) ampliﬁcation level of 168
breast cancer specimens using dual-colour CISH and
FISH and compared the results.
Methods and results: We found 100% agreement
between HER2 status determined by FISH and dual-
colour CISH. Furthermore, we observed that the
time used to score slides was signiﬁcantly reduced
by 28% in dual-colour CISH compared with the
FISH protocol. Concordance between HER2 protein
status and dual-colour CISH or FISH was equally
good with an overall agreement of 96.8%. Correla-
tion between the HER2 ⁄ centromere 17 gene ratios
obtained with dual-colour CISH and FISH was
highly signiﬁcant with an overall correlation coefﬁ-
cient (q) of 0.96.
Conclusions: We conclude that dual-colour CISH and
bright ﬁeld microscopy are excellent alternatives to
FISH when analysing the HER2 status of primary
breast cancer.
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Fluorescence in situ hybridization (FISH) analysis is
based on speciﬁc recognition of denatured target DNA
sequences by ﬂuorescent labelled sequence pairing
probes. Gene ampliﬁcations, deletions, translocations
as well as chromosomal copy number changes are
among the types of genetic aberrations that can be
detected by FISH. It is therefore a powerful technique
used to reveal known genetic alterations relevant to
cancer diagnosis, prognosis and correct treatment
strategies.
The large potential for diagnostic and prognostic use
of FISH is not implemented in all routine pathological
laboratories. This could be due to disadvantages
previously put forward,
1–4 which include certain ﬁxa-
tives interfering with ﬂuorescence detection and limited
community experience with tissue-based FISH. Fur-
thermore, the evaluation of tissue morphology through
FISH is challenging, and the ﬂuorescence signal fades
relatively quickly, making long-term archiving of slides
impossible. Comparisons of FISH with chromogenic
in situ hybridization (CISH) have revealed several
advantages with the use of CISH.
2,3 The CISH tech-
nique is a simple extension of the FISH protocol that
allows bright ﬁeld microscopic evaluation of slides with
the additional beneﬁt that morphological features can
be observed, and that archiving of slides is possible.
Conversion of the FISH to a CISH signal is achieved
using ﬂuorochrome- or hapten-speciﬁc antibodies as an
extension to the FISH probes. These antibodies are
conjugated to an enzymatic marker such as horserad-
ish peroxidase (HRP) or alkaline phosphatase (AP).
These enzymes are visualized by the addition of suitable
substrates and the chromogenic signals can be quan-
tiﬁed using bright ﬁeld microscopy. Until now the CISH
technique has mainly been done using one colour,
although two dual-colour protocols have been devel-
oped and published.
5,6 A major advantage of dual-
colour in situ hybridization (ISH) is that a reference
probe can be utilized, making it easier, faster and more
accurate to distinguish true gene ampliﬁcations from
chromosomal aneuploidy.
7
One major application of FISH in routine pathology
is the determination of human growth factor receptor 2
(HER2) status in primary breast cancer. Overexpression
of HER2 has been documented in approximately 18–
23% of human breast cancers
8 and is considered a poor
prognostic marker.
9 Clinical Phase III studies of trast-
uzumab (Herceptin
 ; Genentech, San Francisco, CA,
USA) in breast cancer have shown a great beneﬁt,
particularly for patients with tumours with HER2 gene
(HER2) ampliﬁcation.
10–12 Current recommendations
of the American Society of Clinical Oncology ⁄ College of
American Pathologists (ASCO ⁄ CAP) include determi-
nation of HER2 status in all invasive breast cancers
using immunohistochemistry or ISH.
8
In this study, we present the data from a pan-
European HER2 assessment study involving ﬁve differ-
ent laboratories. We compared the results obtained
with FISH and a newly available dual-colour CISH
assay for the determination of HER2 status in 168
cases of primary breast cancer.
Methods
tumour specimens
Routine formalin-ﬁxed parafﬁn-embedded breast can-
cer specimens from 168 patients were included in this
study. From each of four pathological laboratories 32
specimens were used and from one pathological labo-
ratory 40 specimens were used. Whole serial sections
were used for the dual-colour CISH and FISH analyses.
The specimens were selected, blinded, stained and
analysed at each of the ﬁve different sites, The
specimens were selected based on their HercepTest
immunohistochemical (IHC) score, so that 25% in each
of the four categories, i.e. 0, 1+, 2+ and 3+, were
represented in the study. Therefore, a total of 42
specimens were encompassed in each of the four HER2
IHC categories overall. Of the 168 specimens used, it
was impossible to detect tumour cells in only one
specimen.
fluorescence in situ hybridization
FISH was conducted using the HER2 FISH pharmDx 
(Dako Denmark A ⁄ S, Glostrup, Denmark). The assay
was performed according to the manufacturer’s rec-
ommendations and subsequently evaluated using a
ﬂuorescence microscope equipped with appropriate
ﬁlters for 4¢-6-diamidino-2-phenylindole, ﬂuorescein
isothiocyanate (FITC) and Texas Red at 60· or 100·
magniﬁcation.
chromogenic in situ hybridization
The dual-colour CISH protocol used is an extension of
the HER2 FISH pharmDx  protocol, where the Texas
Red- and FITC-labelled FISH probes were visualized
using a simple two-step immunohistochemistry stain-
ing procedure. The CISH protocol consisted of the same
initial steps as in the FISH procedure, with the
exception that the ﬁnal dehydration, air-drying and
mounting steps were omitted. Instead, slides were
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150 mmol ⁄ l NaCl, 0.05% Tween 20, pH 7.6) for
3 min. Then excess buffer was tapped away and the
slides carefully wiped dry around the sections with a
tissue. To block intrinsic peroxidase activity, sections
were covered with 200 ll peroxidase block solution
(3% H2O2,1 5m m o l ⁄ l NaN3) for 5 min. Slides were
then washed for 3 min in the wash buffer and this
washing step was repeated with fresh wash buffer.
Excess buffer was tapped off and slides were carefully
wiped dry as previously described. To label the FITC-
and Texas Red-conjugated FISH probes with HRP- or
AP-labelled antibodies, the sections were covered with
200 ll CISH antibody mix containing an HRP-conju-
gated antibody to FITC and an AP-conjugated antibody
to Texas Red in 50 mmol ⁄ l Tris buffer, pH 7.5, and
incubated for 30 min in a humidiﬁed chamber. Slides
were washed twice as above in the wash buffer. Excess
buffer was tapped off and the slides wiped dry as before.
To visualize the AP-conjugated antibodies, sections
were covered with 200 ll red chromogen solution
(Fast Red KL Salt) and incubated for 10 min in a humid
chamber. Slides were washed twice as above. Excess
buffer was tapped off and the slides wiped dry as
before. In order to visualize the HRP-conjugated
antibodies, sections were covered with 200 ll
blue chromogen solution (5-amino-2-[3-[5-amino-1,
3-dihydro-3,3-dimethyl-1-(4-sulfobutyl)-2H-indol-2-
ylidene]-1-propenyl]-3,3-dimethyl-1-(4-sulfobutyl)-3H-
Indolium, ter triﬂuoroacetate) and incubated for
10 min in a humidiﬁed chamber. Slides were then
washed twice as above. Sections were counterstained
Figure 1. Pictures from two HER2 non-ampliﬁed breast cancer specimens stained with the dual-colour chromogenic in situ hybridization
protocol. Red dots represent signals from the HER2 probe, whereas the blue dots represent signals from the CEN-17 reference probe. The
upper panel shows a case where tumour cells have a normal number of red and blue signals at 40· (left) and at 100· (right). The lower
panel shows a case where tumour cells have a slightly elevated number of both red and blue signals, typical of a non-ampliﬁed tumour with
chromosome-17 polysomy.
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matoxylin S3301 diluted 1:5 with distilled or deionized
water) for 5 min, rinsed with wash buffer and
immersed in fresh wash buffer for a minimum of
5 min. Slides were rinsed thoroughly with distilled
water and air-dried or dried for 30 min at 37 C.
Alternatively, CISH staining was performed on a Dako
Autostainer instrument according to the manufac-
turer’s recommendations. Before mounting of the slides
they were cooled to room temperature. They were then
mounted with permanent (non-alcohol and non-xylene
based) mounting media or aqueous mounting media,
and evaluated using a bright ﬁeld microscope at 40· or
60· magniﬁcation. Sections in Figure 2 were photo-
graphed using a BX52 microscope (Olympus, Tokyo,
Japan) with an UPLAN SAPO 60·⁄1.2 water immer-
sion lens and a ColorView III camera (Olympus) and
processed with Olympus ⁄ SIS Cell-F software. Sections
in Figure 1 were photographed using a BX51 micro-
scope (Olympus) equipped with a DP70 digital camera
(Olympus).
scoring of the cish and fish slides
Evaluation of the dual-colour CISH and FISH slides was
performed blind by the observers and according to the
guidelines complementing the Dako HER2 FISH phar-
mDx  kit. One observer at each site scored all local
CISH and FISH slides. For all the tumour specimens the
HER2 and centromere 17 (CEN-17) signals from 20
nuclei were counted and the HER2:CEN-17 ratios were
calculated. If the HER2:CEN-17 ratio was borderline
(1.8–2.2), another 20 nuclei from this specimen were
counted and the HER2:CEN-17 ratio was recalculated
from all 40 nuclei. These ratios were subsequently
converted into a HER2 gene status of normal or
ampliﬁed using the cut-off values seen in Table 1. The
scoring time, i.e. time used by the observer to score
each slide, was recorded using a stopwatch.
statistical analyses
Following scoring by CISH and FISH at the local sites,
the data were combined. The correlation between dual-
colour CISH and FISH results with respect to both gene
copy number and ratios for HER2 and CEN-17 were
analysed and the correlation coefﬁcients calculated.
Concordance between HER2 status in the dual-colour
CISH, FISH and immunohistochemical assays was
evaluated by calculating the percent agreement and
by j statistics.
13 Scoring times of the dual-colour CISH
and FISH evaluations were compared using a paired,
two-tailed t-test. All statistical analyses were performed
using SPSS 16 for Windows (SPSS Inc., Chicago, IL,
USA).
Table 1. Cut-off values for HER2 status in ﬂuorescence
in situ hybridization and dual-colour chromogenic in situ
hybridization
HER2 status Ratio deﬁnitions
Normal HER2:CEN-17 ratio <2.0
Ampliﬁed HER2:CEN-17 ratio ‡2.0
Figure 2. Photomicrographs from two different HER2 ampliﬁed breast cancer specimens stained with the dual-colour chromogenic in situ
hybridization protocol. In both panels the nuclei of tumour cells show numerous red signals (HER2) and a normal number of blue signals (CEN-
17). Breast cancer cells with low HER2 ampliﬁcation are shown in the left panel, and breast cancer cells with high HER2 ampliﬁcation are
shown in the right panel. Normal cells can be observed in both panels constituting a very good internal control for the staining of these cases.
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No data on patient demographics and medical history
were collected, and for all study sites this investigation
was performed in agreement with local regulations and
with the current version of the World Medical Associ-
ation Declaration of Helsinki.
Results
appearance of the dual-colour cish in
primary breast cancer
Representative photomicrographs of dual-colour CISH-
stained primary breast cancer specimens taken at
different laboratories are shown in Figures 1 and 2.
The dual-colour CISH staining resulted in clear and
discernible colours for HER2 (red) and CEN-17 (blue)
that allowed these signals to be counted and quantiﬁed.
In the upper panel of Figure 1 the majority of tumour
cells have nuclei with two red dots representing two
HER2 signals and two blue dots representing two CEN-
17 reference probe signals, indicating that these
tumour cells do not have HER2 ampliﬁcation and
have a normal diploid status with respect to chromo-
some 17. The tumour cells in the lower panel of
Figure 1 also represent a HER2 non-ampliﬁed case. In
this case most of the nuclei have more than two blue
dots, indicating chromosome-17 polysomy. Corre-
spondingly, most tumour cells have nuclei with more
than two red dots indicating the presence of extra
copies of HER2 in these tumour cells.
In Figure 2, photomicrographs of ampliﬁed tumour
cells with many red dots corresponding to several
HER2 signals in the nuclei are observed. Furthermore,
the majority of cells have two blue dots per nuclei
corresponding to a normal diploid status with respect
to chromosome 17. From the photomicrograph in
Figure 2 (right panel), the presence of many HER2
gene copies in the nuclei leads to partially overlapping
red signals that can be seen as highly coalescent areas.
Although this does not pose a risk for the HER2 status
determined for the current specimen, it might lead to a
minor underestimation of the HER2 gene copies
present in these tumour cells.
concordance between dual-colour cish and
fish
A HER2 status of normal or ampliﬁed was assigned to
all breast cancer slides based on the HER2:CEN-17
ratio determined in both the dual-colour CISH and
FISH protocols. Specimens with a HER2:CEN-17 ratio
<2.0 were scored as normal, whereas those with a
HER2:CEN-17 ratio ‡2.0 were scored as ampliﬁed. The
agreement between HER2 status when determined by
dual-colour CISH and FISH analysis was found to be
100.0% (j value = 1.00), corresponding to perfect
agreement between these two methods (Table 2).
Furthermore, to enable comparisons of dual-colour
CISH and FISH with the HercepTest IHC score, scores of
0 and 1+ were regarded as negative (normal), whereas
a score of 3+ was regarded as positive (ampliﬁed).
When comparing the IHC HER2 status, without the
equivocal IHC 2+ cases, with the status obtained in the
dual-colour CISH or FISH protocols, 96.8% agreement
(j value = 0.93) was observed for immunohistochem-
istry versus dual-colour CISH (Table 3) and for immu-
nohistochemistry versus FISH (Table 4).
In Figure 3 individual paired HER2:CEN-17 ratios
determined by the dual-colour CISH and FISH protocols
have been graphed from one of the ﬁve study sites.
Good agreement between the ratios determined by the
two methods is obtained, as was observed with the
other study sites (data not shown). Figure 3 also shows
that from this site one case of IHC 1+ and one case of
Table 2. Crosstabulation of HER2 status for ﬂuorescence
in situ hybridization (FISH) and dual-colour chromogenic
in situ hybridization (CISH)
CISH HER2 status
FISH HER2 status
Total Normal Ampliﬁed
Normal 122 0 122
Ampliﬁed 0 45 45
Total 122 45 167
Agreement 100.0%.
j value 1.00.
Table 3. Crosstabulation of HER2 status for immunohisto-
chemistry (IHC) and dual-colour chromogenic in situ hybrid-
ization (CISH) without IHC 2+ cases
CISH HER2 status
HER2 IHC status
Total Negative Positive
Normal 83 3 86
Ampliﬁed 1 38 39
Total 84 41 125
Agreement 96.8%.
j value 0.93.
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and FISH. This ampliﬁed case of IHC 1+ was subse-
quently re-analysed with HercepTest and veriﬁed to be
a case of IHC 1+. Taken all sites into account, 7.3% of
IHC 3+ cases were found to be normal (negative) by
ISH (data not shown), whereas 1.2% of IHC 0 and 1+
cases were found to be ampliﬁed. Of all IHC 2+ cases,
14.3% were ampliﬁed as determined by the ISH
methods. These observations correspond very well to
previously reported percentages of ampliﬁed cases in
the different IHC categories.
14
Analysis of the correlation between the dual-colour
CISH and FISH methods was performed by plotting the
HER2:CEN-17 ratios, the HER2 copy numbers and the
CEN-17 copy numbers found by the two methods,
followed by linear regression analysis (Figure 4). By
linear regression analysis the results showed highly
signiﬁcant correlations between the methods with
correlation coefﬁcients (q) for: (i) HER2:CEN-17 ratio
at 0.96 (Figure 4A), (ii) HER2 copy numbers at 0.94
(Figure 4B), and (iii) CEN-17 copy numbers at 0.83
(Figure 4C).
Table 4. Crosstabulation of HER2 status for immunohisto-
chemistry (IHC) and ﬂuorescence in situ hybridization (FISH)
without IHC 2+ cases
FISH HER2 status
HER2 IHC status
Total Negative Positive
Normal 83 3 86
Ampliﬁed 1 38 39
Total 84 41 125
Agreement 96.8%.
j value 0.93.
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Figure 3. Individual paired HER2:CEN-17 ratios for dual-colour
chromogenic in situ hybridization and ﬂuorescence in situ hybridiza-
tion. Data are from one of the ﬁve sites and correspond to 32
individual cases (n = 32), with eight cases classiﬁed by the Hercep-
Test protocol in each of the four immunohistochemical categories 0+,
1+, 2+ or 3+. The dotted line illustrates the cut-off value of 2.0.
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Figure 4. A, Correlation between HER2:CEN-17 ratios determined
by dual-colour chromogenic in situ hybridization (CISH) and
ﬂuorescence in situ hybridization (FISH); r = 0.96, P < 0.001
(n = 167). B, Correlation between HER2 copy numbers determined
by dual-colour CISH and FISH; r = 0.94, P < 0.001 (n = 167).
C, Correlation between CEN-17 copy numbers determined by
dual-colour CISH and FISH; r = 0.83, P < 0.001 (n = 167).
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dual-colour CISH and FISH analyses by a paired t-test
revealed a small but signiﬁcant difference between
these ratios, the mean dual-colour CISH ratio being
0.51 lower than the mean FISH ratio (Table 5).
Furthermore, we observed that the mean dual-colour
CISH HER2 copy number was signiﬁcantly different
from the corresponding mean FISH HER2 copy number
in a paired t-test, whereas there was no difference
between the mean CEN-17 copy numbers determined
by FISH and CISH (Table 5).
scoring time for dual colour cish and fish
To enable comparison of the time used to score slides
for the dual-colour CISH and FISH protocols, the time
to score each slide with each of the two methods was
recorded. From these data we could calculate a mean
dual-colour CISH slide scoring time of 3.69 min, and a
mean FISH slide scoring time of 5.10 min (Figure 5).
Therefore, the dual-colour CISH slide scoring time was
found to be 1.41 min shorter (95% conﬁdence interval
1.04, 1.77), which is equal to a signiﬁcant 28%
reduction in scoring time (Figure 5).
Discussion
A quantitative method for rapid, robust and reliable
determination of HER2 ampliﬁcation in breast cancer
specimens is a clinical requirement. This is because
accurate assessment of HER2 status is critical for
identiﬁcation of breast cancer patients that may beneﬁt
from treatment with trastuzumab or lapatinib (Tyk-
erb
 ; GlaxoSmithKline, Brentford, UK),
11,15 and the
response to endocrine treatment of metastatic breast
cancer also appears to be dependent on HER2 sta-
tus.
16,17 Determination of HER2 status in breast cancer
specimens has previously been performed at the level of
HER2 gene copies using Southern blotting, polymerase
chain reaction, FISH or single-colour CISH, or at the
level of HER2 protein using immunoblotting, enzyme
immunoassays or immunohistochemistry. Today,
immunohistochemistry and FISH are the most com-
monly used clinical methods for determining HER2
status in breast cancer, and these techniques, as well as
alternative ISH methods, are currently recommended
by the ASCO ⁄ CAP.
8 Generally, FISH analysis is
considered the gold standard in HER2 testing;
18 how-
ever, as outlined in the Introduction, there are several
limitations and disadvantages of this technique, many
of which can be ameliorated by the use of CISH. The
use of bright ﬁeld microscopy instead of ﬂuorescence
microscopy in the CISH analysis permits easier identi-
ﬁcation of invasive tumour cells, reducing the risk of
analysing non-malignant or non-invasive cells. Fur-
thermore, the use of bright ﬁeld microscopy in CISH
facilitates the discussion of cases for educational
purposes and allows easy evaluation of HER2 status
in tissue microarrays prepared for research. One major
advantage with the use of CISH is the possibility to
store slides in general archives at room temperature,
which allows re-evaluation of cases as well as retro-
spective studies.
Table 5. Mean HER2:CEN-17 ratios and HER2 and CEN-17
copy numbers for ﬂuorescence in situ hybridization (FISH)
and dual-colour chromogenic in situ hybridization (CISH) for
all specimens in the study
Mean SEM SD
FISH HER2:CEN-17 ratio 3.08 0.34 4.36
CISH HER2:CEN-17 ratio* 2.57 0.26 3.40
FISH HER2 copy number 5.74 0.54 6.94
CISH HER2 copy number† 4.88 0.47 6.03
FISH CEN-17 copy number 2.02 0.051 0.66
CISH CEN-17 copy number 2.00 0.051 0.66
Gene copy numbers correspond to the mean copy number
per cell of the 20 (or 40) nuclei counted (n = 167).
*Signiﬁcantly different from the FISH HER2:CEN-17 ratio
(P < 0.001, paired two-tailed t-test).
†Signiﬁcantly different from the FISH HER2 copy number
(P < 0.001, paired two-tailed t-test).
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Figure 5. The mean scoring times per slide in the dual-colour
chromogenic in situ hybridization (CISH) and ﬂuorescence in situ
hybridization (FISH) analysis. The 95% conﬁdence interval is shown
as the error bar. There is a signiﬁcant 28% difference in mean scoring
time between the two methods (P < 0.001, two-tailed paired t-test,
n = 167).
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to be a useful alternative to FISH, and in several studies
the concordance levels of HER2 status between single-
colour CISH and FISH were found to be in the range of
91–100%.
1,2,7,19–26 However, a single-colour CISH
system is limited, as only one type of signal can be
evaluated on the section, and HER2 breast cancer
specimens that do not have a clear non-ampliﬁed or
highly ampliﬁed HER2 status should be retested on a
serial section for a possible chromosome 17 polysomy.
This strategy is time consuming and cost ineffective
and may delay the ﬁnal determination of HER2 status.
In this study we have analysed HER2 ampliﬁcation in
primary breast cancer using a novel, quantitative, dual-
colour CISH protocol that converts Texas Red and FITC
ﬂuorescent FISH signals to chromogenic red and blue
signals, respectively.
27 In comparison with previous
CISH protocols, this dual-colour CISH protocol features
simultaneous determination of HER2 probe signals and
chromosome 17 probe signals, thereby eliminating the
need for a second round of analysis of chromosome 17
polysomy.Inthisanalysis,wehavecomparedtheresults
of the dual-colour CISH protocol with that of a reference
Food and Drug Administration-approved FISH protocol
(Dako HER2 FISH pharmDx ) and, to our knowledge,
this is the ﬁrst multicentre evaluation of the dual-colour
CISH kit.
This analysis has revealed a signiﬁcant correlation of
copy numbers for HER2, CEN-17 and the HER2:
CEN-17 ratio between the dual-colour CISH and FISH
protocols, which is in agreement with previous reports
on the overall good agreement between single-colour
CISH and FISH. We here report a 100% concordance in
HER2 status between dual-colour CISH and FISH as
well as a signiﬁcant 28% reduction in scoring time
when using the dual-colour CISH protocol compared
with FISH. Our combined data document that the dual-
colour CISH protocol is a reliable and robust analysis
method for HER2 testing in breast cancer.
We also observed that the mean dual-colour CISH
HER2 copy number and the mean HER2:CEN-17 ratio,
but not the mean CISH CEN-17 copy number of the 167
cases were signiﬁcantly lower than those determined by
FISH.Thisdifferencemightbeduetoanunderestimation
of HER2 copy numbers in ampliﬁed cases determined
usingthedual-colourCISHprotocol.Asalreadyreported,
the number of HER2 gene copies in the nuclei can be
underestimated in areas of high-level ampliﬁcation due
tooverlappingdotsthatleadtocoalescingsignalclusters
(see Figure 2).
19 This is further supported by the obser-
vation that there is no signiﬁcant difference between the
mean HER2 copy numbers found by the two methods
when testing the subset of cases with FISH HER2 copy
numbers £2.5 per nucleus (data not shown), whereas
when analysing the subset of cases with a FISH HER2
copynumber>2.5pernucleus,thedual-colourCISHand
FISH methods gave signiﬁcantly different results (data
not shown). Because this discrepancy is statistically
relevant only at elevated HER2 copy numbers, there is
little risk that this could obscure the HER2:CEN-17 ratio
ofborderlinecases,whichwasalsoseenbytheabsenceof
discordantcasesinthisstudyof167cases.Itshould also
be noted that a similar trend with dual-colour CISH has
beenobservedpreviouslyinarelativelysmallsampleset,
andalsointhisinstancethistrenddidnothaveanyeffect
on the overall validity of the assay end-point.
27
We conclude that the dual-colour CISH protocol used
in this study is a reliable and robust analysis method
that has additional beneﬁts when compared with
traditional FISH and single-colour CISH protocols used
for HER2 testing in breast cancer.
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